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Abstract 
Intervertebral disc degeneration (IDD) causes 
chronic back pain and is linked to production of 
proinflammatory molecules by nucleus pulposus 
(NP) and other disc cells. Activation of Tonicity-
Responsive Enhancer-Binding Protein 
(TonEBP)/NFAT5 by non-osmotic stimuli, 
including pro-inflammatory molecules, occurs in 
cells involved in immune response. However, 
whether inflammatory stimuli activate TonEBP in 
NP cells and if TonEBP controls inflammation 
during IDD is unknown. We show that TNF-α, but 
not IL-1β or LPS, promoted nuclear enrichment of 
TonEBP protein. However, TNF-α-mediated 
activation of TonEBP did not cause induction of 
osmo-regulatory genes. RNA-sequencing showed 
that 8.5% of TNF-α transcriptional responses were 
TonEBP-dependent and identified genes regulated 
by both TNF-α and TonEBP. These genes were 
over-enriched in pathways and diseases related to 
Inflammatory Response and Inhibition of Matrix 
Metalloproteases. Based on RNA-seq results, we 
further investigated regulation of novel TonEBP 
targets CXCL1, CXCL2, and CXCL3. TonEBP 
acted synergistically with TNF-α and LPS to 
induce CXCL1 proximal promoter activity. 
Interestingly, this regulation required a highly 
conserved NF-κB binding site but not a predicted 
TonE, suggesting crosstalk between these two 
members of the Rel family. Finally, analysis of 
human NP tissue showed that TonEBP expression 
correlated with canonical osmo-regulatory targets 
TauT/SLC6A6, SMIT/SLC5A3, and AR/AKR1B1, 
supporting in vitro findings that the inflammatory 
milieu during IDD does not interfere with TonEBP 
osmoregulation. In summary, while TonEBP 
participates in the pro-inflammatory response to 
TNF-α, therapeutic strategies targeting this 
transcription factor for treatment of disc disease 
must spare osmo-protective, pro-survival, and 
matrix homeostatic activities.  
 
Introduction 
The transcription factor TonEBP, or 
NFAT5, is essential for the coordinated response 
of mammalian cells to osmotic stimuli, which 
includes the accumulation of non-ionic organic 
osmolytes and heat shock proteins that prevent 
damage to cellular proteins and nucleic acids (1). 
Nucleus pulposus (NP) cells of the healthy 
intervertebral disc are subject to a hyperosmotic 
environment, which fluctuates with daily postural 
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changes (2, 3). Previously, we have shown that 
TonEBP regulates survival of NP cells and 
maintains transcription of genes necessary for 
matrix homeostasis under hyperosmotic conditions 
(4–6). However, the regulation of TonEBP under 
inflammatory conditions and its role in disc 
degeneration remain unexplored. 
Intervertebral disc degeneration (IDD) is 
an important risk factor for chronic low back and 
neck pain (7) which is a ubiquitous and costly 
pathological condition (8) that contributes heavily 
to disability in the U.S. and worldwide (9–11). 
During IDD, changes in both cellular behavior and 
ECM makeup ultimately compromise 
biomechanical function of the disc. NP and other 
disc cells produce cytokines including Tumor 
Necrosis Factor-alpha (TNF-α)/TNF and IL-1β, 
which contribute to an inflammatory environment 
through NF-κB and MAPK signaling pathways 
and promote production of matrix-degrading 
MMP and ADAMTS family members (12–16). 
Catabolism of the NP extracellular matrix limits 
its water-binding capacity, eventually leading to a 
stiffer matrix, decreased disc height, and altered 
mechanical loading (17, 18). Moreover, excessive 
mechanical loading (19) and matrix breakdown 
products (20) can also activate toll-like receptors 
(TLRs) expressed on NP cells.  
Interestingly, independent of 
hyperosmolarity, TonEBP/NFAT5 expression is 
induced in response to inflammatory stimuli, 
including IFN-γ and IL-4 (21), in immune cells. 
Likewise, TonEBP can be induced by TLR 
activation through LPS (21–23), E. coli (22), or M. 
tuberculosis (24). Following LPS stimulation, 
TonEBP is required for antimicrobial response 
through regulation of NOS2 and other target genes 
(23). Moreover, in fibroblast-like synoviocytes 
derived from rheumatoid arthritis patients, TNF-α 
and IL-1β induce levels and nuclear localization of 
TonEBP. In these cells, TonEBP controls cell 
survival, proliferation, migration, and 
angiogenesis (25). However, whether such 
changes in TonEBP activation occur during disc 
degeneration is not known. 
In the present study, we investigated 
whether TonEBP is activated by pro-inflammatory 
stimuli in NP cells and its role in this context. 
TonEBP activity, but not expression, was 
modulated by pro-inflammatory stimuli in NP 
cells. Importantly, TNF-α-induced TonEBP 
selectively controls inflammatory gene expression 
without affecting its canonical osmoregulatory 
targets. Our results clearly suggest that TonEBP is 
critical for TNF-α-mediated expression of several 
molecules thought to play a key role during disc 
degeneration.   
 
Results 
TNF-α  promotes TonEBP nuclear localization 
without affecting transcript levels 
Previous studies in immune cells and RA-FLS 
have shown activation of TonEBP/NFAT5 by 
various inflammatory stimuli, including TNF-α. 
Therefore, we investigated if TNF-α, IL-1β, and 
LPS promote TonEBP expression in NP cells. 
Interestingly, none of these pro-inflammatory 
stimuli affected TonEBP mRNA levels, although 
induction was seen with hyperosmolarity (Fig. 
1A). We evaluated levels of total TonEBP protein 
following 4 to 24 h stimulation with TNF-α, IL-
1β, and LPS and found no significant differences 
with stimulation (Fig. 1B and C). Surprisingly, 
only treatment with TNF-α significantly increased 
the nuclear pool of TonEBP protein (Fig. 1D and 
E), while neither IL-1β (Fig. 1F and G) nor LPS 
(Fig. 1H and I) treatment had any effect on nuclear 
enrichment of TonEBP. This response is different 
than what has been reported for immune cells and 
fibroblast-like synoviocytes (21, 25). A similar 
enrichment in nuclear TonEBP was observed with 
immunofluorescent staining (Fig. 1J).  
 
TonEBP activation under inflammatory 
conditions fails to induce transcription of osmo-
regulatory target genes 
Nuclear accumulation of TonEBP is a shared 
feature of response to hyperosmolarity and TNF-α 
and an important indicator of TonEBP activation. 
We wanted to investigate if TNF-α, and 
inflammatory stimuli such as IL-1β and LPS that 
do not affect nuclear translocation, can modulate 
phosphorylation status of the TonEBP 
transactivation domain (TAD). Activity of the 
TonEBP-TAD (amino acids 548-1531) was 
assessed using a binary GAL4 system, as depicted 
in Fig. 2A. Interestingly, addition of TNF-α, IL-
1β, or LPS had no effect on Ton-TAD activity 
(Fig. 2B). As expected, treatment with NaCl 
induced TonTAD activity. Interestingly, TAD 
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induction by NaCl was inhibited by co-treatment 
with TNF-α, but not IL-1β or LPS (Fig. 2B). We 
then assessed the activity of the proximal TauT 
promoter, which contains a highly conserved 
TonEBP binding site (TonE) shown to be active in 
NP cells (Fig. 2C) (4, 26). Similar, to TonEBP-
TAD, TNF-α, IL-1β, and LPS did not affect 
activity, while NaCl strongly induced promoter 
activity (Fig. 2D). Since TNF-α promoted 
TonEBP nuclear translocation, we investigated 
whether mRNA levels of traditional osmo-
regulatory TonEBP target genes TauT/SLC6A6, 
SMIT/SLC5A3, and AR/AKR1B1 were affected by 
TNF-α as well as IL-1β and LPS. None of these 
target genes were significantly induced by pro-
inflammatory stimuli; again, levels were elevated 
by treatment with NaCl (Fig. 2E-G). Finally, we 
investigated whether co-treatment of TNF-α along 
with NaCl would affect inducibilty of osmo-
regulatory targets. TauT, SMIT, and AR were all 
significantly induced by treatment with 24 h NaCl 
alone. Addition of TNF-α along with NaCl did not 
impact inducibilty of TauT, SMIT, or AR (Fig. 
2H).  
 
RNA sequencing reveals TonEBP as a critical 
regulator of NP cell response to TNF-α  
Since our results suggested that TNF-α and other 
inflammatory stimuli do not induce TonEBP 
targets concerned with cellular osmo-sensing, we 
employed an -omics approach to identify the 
unique transcriptional targets of TonEBP during 
TNF-α stimulation. We performed RNA 
sequencing on rat NP cells that were transduced 
with either lentivirally-delivered ShControl or 
ShTonEBP with or without TNF-α treatment for 
24 h. TonEBP controlled expression of 405 genes 
in untreated cells and 371 genes under TNF-α 
stimulation (Fig. 3A). Importantly, while some 
TonEBP targets were shared between untreated 
and TNF-α-treated NP cells, a substantial number 
were treatment-specific (Fig. 3B). Furthermore, 
RNA-seq identified 1,339 genes that were 
differentially expressed between basal and TNF-α-
treated groups (Fig. 3C). We found that, out of all 
genes differentially regulated by TNF-α, 50.6% 
were positively and 49.4% were negatively 
regulated. We then determined what proportion of 
the transcriptional output of TNF-α could be 
attributed to TonEBP in NP cells. Overall, out of 
all genes modulated by TNF-α, 8.5% were also 
regulated by TonEBP (Fig. 3D). Of the genes 
positively regulated by TNF-α, 12.1% (Fig. 3E) 
showed positive and 1.3% showed negative 
correlation with TonEBP. Likewise, of genes 
negatively regulated by TNF-α, 0.3% were 
positively and 4.8% were negatively correlated 
with TonEBP (Fig. 3E). Since TNF-α is closely 
linked to enhanced matrix catabolism and 
inflammation during disc degeneration, we 
decided to focus on genes that were positively 
regulated by both TNF-α and TonEBP and 
performed Ingenuity Pathway Analysis (IPA) on 
this subset of genes. Several pathways important 
in the context of disc degeneration and metabolism 
emerged, including Inhibition of Matrix 
Metalloproteases, IL-17-related pathways, and 
HIF-1α signaling (Supplemental Table 1). Top 
Diseases and Disorders included Inflammatory 
Response, Connective Tissue Disorders, and 
Skeletal and Muscular Disorders (Supplemental 
Table 2). Networks associated with this gene list 
included Hematological System Development and 
Function, Inflammatory Response, and Tissue 
Morphology and Cellular Movement, Connective 
Tissue Development and Function, Tissue 
Development (Supplemental Table 3). Log2 (-fold 
change) values from RNA-seq results for select 
genes in these identified pathways is shown in Fig. 
3F. These genes were significantly different 
between indicated experimental groups, as defined 
by adjusted p-value < 0.05. We also validated 
some of the TonEBP targets shown in Fig. 3C that 
were most closely linked to disc degeneration 
using qRT-PCR and ELISA. As seen before, 
TonEBP and TauT levels were unaffected by TNF-
α treatment but, expectedly, decreased with 
TonEBP silencing (Fig. 4A). Expression of genes 
associated with matrix catabolism such as 
ADAMTS4, ADAMTS5, and MMP3 were all 
decreased by TonEBP knockdown in the presence 
of TNF-α (Fig. 4B). In addition, we investigated 
how expression of key NP matrix molecules 
known to be suppressed by TNF-α were affected 
by TonEBP silencing. The suppressive effect of 
TNF-α on ACAN and COL2A1 was not changed 
by TonEBP knockdown (Fig. 4C). This is likely 
due to the fact that TonEBP has been shown to 
positively regulate these genes in NP and 
chondroprogenitor cells (4, 27). 
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Additionally, we studied expression of several 
cytokines, chemokines, and regulators of the 
inflammatory response in TonEBP-silenced NP 
cells under TNF-α stimulation. TNF-α induced 
mRNA levels of TNF, NOS2, PHD3, and TLR2 
and this induction was significantly decreased 
following TonEBP knockdown (Fig. 5A). 
Similarly, we measured mRNA and protein levels 
of CCL2 and IL-6 in TonEBP-silenced cells. Both 
genes were induced by TNF-α treatment (Fig. 5B). 
The transcript and protein levels were significantly 
suppressed by TonEBP knockdown following 
TNF-α treatment (Fig. 5B-D).  
 
TonEBP promotes TNF-α-mediated induction of 
CXCL1, CXCL2, and CXCL3 
Our RNA-seq results suggested that TonEBP 
regulated expression of CXCL2 and CXCL3. 
Therefore, we further investigated regulation of 
CXCL family members by TonEBP in NP cells. 
Treatment with TNF-α induced mRNA levels of 
CXCL1, CXCL2, and CXCL3, which were 
significantly decreased in TonEBP-knockdown NP 
cells (Fig. 5E). In order to evaluate levels of 
CXCL proteins, we collected conditioned media 
from control and TonEBP-knockdown cells and 
performed immunoblots. We found that TNF-α-
mediated induction of CINC1/CXCL1, 
CINC3/CXCL2, and CINC2/CXCL3 protein was 
also inhibited in TonEBP-silenced cells (Fig. 5F).  
 
TonEBP controls activity of the CXCL1 promoter 
via a highly conserved NF-κB binding site 
To investigate whether TonEBP acts directly on 
the CXCL1 promoter, we studied the proximal (1.5 
kB) promoter region of the rat CXCL1 gene. Using 
MatInspector software, we searched for potential 
TonE’s in the promoter, finding only a single site 
using a prediction score cutoff of 0.8, in addition 
to five NF-κB sites predicted earlier (28). To test 
the effects of various stimuli on the CXCL1 
promoter, we measured activity of a wild-type 
promoter-luciferase reporter construct (Fig. 6A). 
Similarly, we measured activities of the construct 
with the predicted TonE mutation and a construct 
with the mutation in the most active NF-κB site, 
which was experimentally validated in a previous 
study (four other NF-κB sites are wild-type) (28). 
To test whether TonEBP controls activity of the 
CXCL1 promoter and its mode of regulation, we 
overexpressed either wild-type (TonEBP) or 
dominant-negative (DN-TonEBP) TonEBP and 
measured activities of wild-type as well as mutant 
promoters. Surprisingly, while TonEBP induced 
activity of both wild-type and TonE-mutant 
CXCL1 promoters, it had no effect on the NF-κB-
mutant promoter (Fig. 6B). Moreover, DN-
TonEBP had no effect on any of the promoters 
under basal conditions (Fig. 6B). We then 
explored whether modulation of TonEBP would 
impact the responsiveness of these promoters to 
various inflammatory stimuli. We found that 
overexpression of TonEBP enhanced the inductive 
effect of TNF-α on the wild-type and TonE-
mutant promoters. While TNF-α increased activity 
of NF-κB-mutant, TonEBP failed to further induce 
this activity (Fig. 6C). On the other hand, TonEBP 
overexpression had no synergistic effect on IL1-β-
mediated induction in activity of wild-type and 
TonE-mutant promoters. IL-1β did not affect 
activity of NF-κB mutant and there was no 
modulation by co-expression of TonEBP. 
However, DN-TonEBP blocked IL-1β-mediated 
induction in wild-type and TonE-mutant promoter 
activity. Again, there was no effect of DN-
TonEBP on the NF-κB-mutant promoter (Fig. 
6D). In contrast to TNF-α and IL-1β treatment, 
LPS alone did not induce activity of any of the 
promoters. Interestingly, induction of wild-type 
promoter activity is seen when LPS is combined 
with TonEBP overexpression and to a lower extent 
with TonE mutation; again, there was no effect on 
NF-κB-mutant (Fig. 6E). Finally, we added a 
small dose of p65 plasmid such that further 
induction of the promoter could be achieved, and 
evaluated the ability of TonEBP to modulate its 
effects on the CXCL1 promoter. While there was a 
trend of increased activity of all three promoters 
(wild-type, TonE-, and NF-κB-mutant) in 
presence of p65, it did not reach statistical 
significance. However, TonEBP co-expression 
was able to enhance activity of all promoters, 
including the NF-κB-mutant (Fig. 6F). We further 
examined the ability of TonEBP to act 
synergistically with NF-κB signaling by 
measuring activity of an NF-κB reporter in 
response to TNF-α treatment along with TonEBP. 
While TNF-α alone induced NF-κB reporter 
activity, expression of TonEBP further enhanced 
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this effect (Fig. 6G). To test whether crosstalk 
between osmotic-response and inflammatory 
pathways impacted CXCL1 response to TNF-α, 
we measured mRNA expression following 
treatment with NaCl alone, TNF-α alone, or NaCl 
with TNF-α. We found that CXCL1 expression 
was unaffected by NaCl and was induced by TNF-
α. Furthermore, co-treatment with NaCl and TNF-
α did not impact inducibilty by TNF-α (Fig. 6H).  
 
TonEBP controls the CXCL2 promoter under 
specific stimuli 
Because CXCL1 and CXLC2 showed similar 
patterns of expression in response to TNF-α 
stimulation and TonEBP modulation, we 
investigated regulation of the CXCL2 promoter as 
well. MatInspector analysis predicted two TonEs 
in the 1.5 kB proximal promoter fragment (Fig. 
7A) along with two previously-predicted NF-κB 
sites, one of which is highly conserved (28). 
Interestingly, Multiz alignment of the rat and 
human genomes showed no evolutionary 
conservation of these TonEs, suggesting relatively 
low likelihood of physiological importance. We 
therefore chose to study only the wild-type and 
NF-κB-mutant (mutation of more highly 
conserved NF-κB site) promoters in these studies. 
Wild-type CXCL2 promoter showed induction in 
activity by TNF-α (Fig. 7B), IL-1β (Fig. 7C), and 
LPS (Fig. 7D). The induction by IL-1β and LPS 
was lost when the NF-κB site was mutated, while 
TNF-α-mediated induction was decreased by 
mutation, suggesting that this site was important 
for mediating response to inflammatory stimuli. 
Interestingly, while TonEBP overexpression 
resulted in synergistic activation of wild-type 
promoter only in the presence of LPS stimulation, 
DN-TonEBP had no effect on promoter activity in 
the presence of any inflammatory stimuli (Fig. 7B-
D). We then tested the effect of a small dose of 
p65 along with TonEBP modulation on the 
CXCL2 promoter activity. Surprisingly, both the 
wild-type and NF-κB mutant promoters were 
induced by p65. While there was a trend of 
TonEBP further inducing wild-type reporter 
activity, this was significant in the case of NF-κB-
mutant reporter (Fig. 7E), underscoring the 
possible contribution of TonEBP in enhancing 
activity of p65. DN-TonEBP did not block p65-
mediated induction of either the wild-type or 
mutant reporter (Fig. 7E). Finally, we measured 
CXCL2 response to TNF-α in the presence or 
absence of NaCl. Similar to CXCL1, mRNA 
expression of CXCL2 was unaffected by NaCl, 
induced by TNF-α treatment, and this induction 
was not affected by co-treatment with NaCl (Fig. 
7F). Similarly, hyperosmolarity did not affect 
TNF-α-dependent expression of PHD3 or TLR2; 
induction of MMP3 was decreased in the presence 
of NaCl (Supplemental Figure 1A-C). 
 
TonEBP expression is maintained during human 
disc degeneration and regulates osmo-protective 
target genes 
To investigate changes in TonEBP during human 
disc degeneration, we measured its expression in 
human tissue samples. Percent of TonEBP 
immunopositive cells was unchanged between 
non-degenerated (grade  4) and degenerated 
(grade >4) samples (Fig. 8A and B). Finally, we 
investigated the relationship between expression 
levels of TonEBP and its osmo-regulatory targets 
in human tissues. Because of limited RNA 
quantity, we found that HPRT1 expression was not 
detectable in all samples. In order to find a suitable 
housekeeping gene whose expression level could 
be readily detected in all samples, we performed 
correlation analysis of HPRT1, 18S, and GAPDH 
expression in all human samples. Levels of 18S 
and GAPDH correlated well in all samples, and 
both HPRT1 correlated with each of these in 
samples where HPRT1 was detectable 
(Supplemental Figure 2A-C). We found strong 
correlations between TonEBP and TauT, SMIT, 
and AR in these samples (Fig. 8 C-E).  
 
Discussion 
Previous work has demonstrated that 
TonEBP is required for survival and function of 
nucleus pulposus (NP) cells in the osmotically 
challenging environment of the intervertebral disc 
(4–6). In the healthy NP, abundant proteoglycans 
and collagen afford the tissue high osmotic 
pressure (29). Furthermore, osmolarity of the NP 
is dynamic due to diurnal posture changes: water 
is effluxed with loading during the day and 
imbibed when loading is relieved at night (30–32). 
We have shown that, in healthy NP cells, TonEBP 
regulates genes involved in cell survival, matrix 
homeostasis, and water transport in response to 
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hyperosmolarity (4–6, 33). However, the role of 
TonEBP in a degenerative disc, characterized by 
tissue inflammation and enhanced matrix 
catabolism, is unknown (16, 34). Importantly, 
while osmotic loads in the healthy NP reach 450-
550 mOsm/L, this number declines in 
degenerating discs (35). Another classic feature of 
disc degeneration is the presence of inflammatory 
cytokines including TNF-α (36) and IL-1β (37, 
38), which promote matrix degradation (13, 14, 
39, 40), chemokine secretion (41, 42), cellular 
senescence (43), and autophagy (44). The aim of 
this study was to determine the activity and role of 
TonEBP under inflammatory conditions that 
define the degenerative intervertebral disc milieu.  
In NP cells, TNF-α treatment promoted 
nuclear localization of TonEBP without affecting 
mRNA or total protein levels. This is in contrast to 
osmotic activation of TonEBP, which comprises 
rapid mRNA induction, increase in total protein 
abundance, and nuclear translocation (45–47). 
Moreover, our result is in partial agreement with a 
previous report showing that TNF-α and IL-1β 
(25) can enhance both total and nuclear fraction of 
TonEBP in other cell types. Further experiments 
highlighted differences between TonEBP 
activation by osmotic and inflammatory stimuli. 
Increased activity of TonEBP-TAD is a critical 
feature of osmotic stimulation of TonEBP activity 
(48). In contrast, treatment with TNF-α, IL-1β, or 
LPS did not increase TAD reporter activity. 
Importantly, genes considered to be faithful 
TonEBP targets were not induced by any of these 
inflammatory mediators in NP cells, despite 
evidence of increased nuclear localization of 
TonEBP by TNF-α. These results suggest that the 
mechanism of TonEBP activation differs 
substantially between osmotic and inflammatory 
conditions. It is plausible that TonEBP target 
selectivity may depend on TAD activation status, 
as has been demonstrated for other transcription 
factors expressed in the NP niche (49). 
Interestingly, previous studies suggest that 
crosstalk exists between osmotic and 
inflammatory response pathways. In RPE cells, 
high salt enhances IL-6 and CCL2 production in 
response to LPS (50). However, in human 
neutrophils and mononuclear cells, high salt 
reduces production of pro-inflammatory cytokines 
in response to LPS treatment (51). A 2013 study 
by Kim et al. showed that both high salt and LPS 
induce TonEBP in macrophages via different 
sources of reactive oxygen species. In these cells, 
high salt and LPS had reciprocal effects on 
TonEBP target genes: pre-treatment with LPS 
dampened the osmo-protective response to high 
salt and pre-treatment with NaCl decreased LPS-
mediated induction of IL-6 (22). In contrast, our 
studies show that, while TNF-α influences 
TonEBP-TAD activation status, the effect on 
hyperosmolarity-dependent induction of TauT, 
SMIT, and AR, canonical osmoregulatory TonEBP 
targets, is minimal. Thus, the outcome of crosstalk 
between inflammatory and osmotic stimuli 
appears to be cell type specific. 
 Despite increased nuclear TonEBP, there 
was lack of induction of canonical osmo-
regulatory TonEBP targets by TNF-α, which 
prompted us to perform RNA-seq to identify novel 
TonEBP targets in this context. Results of these 
experiments clearly showed that TonEBP governs 
pathways and functional categories related to 
inflammatory response, matrix degradation, tissue 
fibrosis, and interleukin signaling during TNF-α 
treatment of NP cells. We found that TonEBP 
controls TNF-α-dependent expression of 
ADAMTS4, ADAMTS5, and MMP3, matrix 
degrading enzymes implicated in disc 
degeneration (12–14). Likewise, TonEBP 
controlled expression of, PHD3, a recently 
identified regulator of NF-κB signaling in NP cells 
(52). In addition, TonEBP modulated levels of 
TNF, NOS2, TLR2, CCL2, and IL-6, molecules 
usually linked to tissue inflammation. These 
results are in agreement with previous studies in 
macrophages that showed TonEBP plays a role in 
TLR-triggered induction of NOS2, IL6, TNF, and 
CCL2 (23). Interestingly, we, and others, have 
shown that levels of CCL2, IL6, NOS2, and TNF 
are also transiently induced by hyperosmolarity in 
a TonEBP-dependent manner (6, 53, 54). 
Importantly, RNA-seq data revealed that only 
about 8.5% of the TNF-α-mediated response in 
NP cells is TonEBP-dependent. Concerning matrix 
homeostasis, suppression of ACAN and COL2A1 
by TNF-α was not TonEBP-dependent. On the 
contrary, both of these critical matrix genes have 
been described as transcriptional targets of 
TonEBP under basal and hyperosmolar conditions 
(4, 55, 56). These results suggest that modulation 
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of TonEBP activity may not fully reverse 
transcriptional changes mediated by TNF-α in NP 
cells.  
In addition to these catabolic and 
inflammatory genes, our results show for the first 
time that TonEBP controlled TNF-α-dependent 
expression of CXCL1/CINC1, CXCL2/CINC3, 
and CXCL3/CINC2. Studies have detected 
expression of CXCL1, CXCL2, and CXCL3 in both 
healthy and degenerative NP tissues with some 
changes in disc infiltrated by immune cells (38). 
Underscoring the importance of CXCL1/CINC1, 
administration of anti-CINC1 antibody 
significantly decreased pain in a murine model of 
disc herniation, as measured by mechanical and 
thermal hyperalgesia (57). Traditionally 
considered chemoattractants for macrophages and 
neutrophils, the function and molecular regulation 
of CXCL1, CXCL2, and CXCL3 expression in the 
intact, immune privileged disc is unknown. 
Interestingly, NP cells express CXCR2, a receptor 
for both CINC1 and CINC3, and receptor 
expression increases with grade of degeneration 
(58), suggesting that these chemokines may act on 
NP cells in an autocrine or paracrine manner and 
play a role in normal tissue physiology. On the 
other hand, following structural damage to the NP, 
such as herniation, we hypothesize that high levels 
of these CXCL family members would drive 
macrophage and neutrophil migration. Our studies 
of the CXCL1 promoter revealed an unexpected 
mode of regulation; the effects of TonEBP 
required the presence of a highly active NF-κB 
binding site (-641/-632), but not the predicted 
TonE (-124/-127). This result raised the question 
of whether TonEBP might interact with p65 at this 
NF-κB binding site. Indeed, Roth and colleagues 
have shown that TonEBP interacts with NF-κB 
binding sites of TNF, CCL2, and IκBα in response 
to hyperosmolarity, presumably as part of a NF-
κB-TonEBP complex (59). In macrophages, 
TonEBP plays a role in activation of LPS-induced 
NF-κB activity by recruiting the transcriptional 
co-activator p300 to the NF-κB enhanceosome 
(60). Likewise, we have previously shown that 
NF-κB activity is required for hyperosmotic 
induction of a subset of TonEBP targets and that 
NF-κB activation by hyperosmolarity depends on 
functional TonEBP (6).  However, these studies 
also showed that TonEBP was not 
immunoprecipitated with p65 under conditions of 
either hypertonicity or TNF-α stimulation, 
suggesting either a very transient nature of 
interaction between these proteins or lack thereof 
(6). The synergistic action of TonEBP and TNF-α 
on the CXCL1 promoter and NF-κB prototypic 
reporter support the possibility of a transient 
interaction between TonEBP and p65 and/or other 
NF-κB subunits, including p50. Interestingly, the 
ability of TonEBP to regulate the CXCL1 and 
CXCL2 promoters varied between inflammatory 
mediators, suggesting stimulus-specific 
mechanisms of regulation. Importantly, our results 
suggest that the highly conserved NF-κB binding 
site in the CXCL2 promoter is important in 
mediating response to inflammatory stimuli and 
that the less conserved TonE’s may not mediate 
the observed effects of TonEBP on TNF-α-
mediated CXCL2 transcription. Moreover, results 
of p65 and TonEBP co-transfections show that 
TonEBP may enhance activity of p65 even on a 
less conserved NF-κB binding site, such as the 
wild-type NF-κB site #1 in the CXCL2 NF-κB-
mutant promoter. Similar to experiments that 
investigated the effect of TNF-α on 
osmoregulatory genes, we did not observe 
modulation of inflammatory TonEBP targets 
CXCL1 and CXCL2 by hyperosmolarity. There 
was also no effect of co-treatment with TNF-α and 
hyperosmolarity on TNF-α-mediated induction of 
CXCL1 and CXCL2 expression. These results 
suggest that, unlike in macrophages, in NP cells 
hyperosmolarity does not inhibit TonEBP action 
on these inflammatory target genes.  
We evaluated TonEBP levels in human 
samples from healthy and degenerative discs. 
While the number of TonEBP-positive NP cells 
was unaffected by degeneration, we did not 
quantitatively measure changes in nuclear protein 
level on a per cell basis because of limited amount 
of tissue sample. Importantly, however, strong 
correlation between expression levels of TonEBP 
and its canonical osmo-regulatory targets TauT, 
SMIT, and AR supports in vitro findings and 
reflects the fact that the inflammatory milieu of 
disc degeneration does not interfere with the 
ability of TonEBP to act on its osmo-regulatory 
targets.  
Together, our results show that TNF-α 
activates TonEBP by promoting its nuclear 
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localization to regulate expression of a subset of 
the TNF-α-induced inflammatory response in NP 
cells (Schematic Fig. 8F). These results invite the 
possibility that targeted TonEBP inhibition might 
be a novel therapeutic strategy to treat disc 
degeneration. Indeed, TonEBP heterozygosity 
partially protects mice from CFA-induced arthritis 
(61). However, it is important to consider the pro-
survival, matrix homeostatic, and other 
physiological activities of TonEBP in the NP 
when developing such a therapy.  
 
Experimental Procedures 
Isolation and Treatment of NP Cells - Rat NP cells 
were isolated using a method described previously 
(62). Collection of animal tissues for cell isolation 
was approved by Thomas Jefferson University 
IACUC. Cells were maintained in DMEM with 
10% FBS and antibiotics. For hypertonic culture, 
110 mM NaCl was added to medium; for TNF-α 
treatment, 50 ng/mL was added to medium; for IL-
1β treatment, 10 ng/mL was added to medium; for 
LPS treatment, 2 ng/mL was added to medium. 
Human tissue collection and grading - Human 
lumbar IVD tissue was obtained either at surgery 
or post-mortem (PM) examination with informed 
consent of the patient or relatives (Sheffield 
Research Ethics Committee #09/H1308/70). Four 
PM IVDs were recovered from 3 donors. They 
consisted of intact IVDs within the complete 
motion segment from which the IVDs were 
removed. Sixty surgical IVD tissue samples were 
obtained from patients undergoing 
microdiscectomy procedures for the treatment of 
low back pain and root pain caused by prolapse of 
the IVD. NP tissue was divided into two: one half 
was fixed in 10% neutral buffered formalin and 
processed for histological and 
immunohistochemical examination and remaining 
tissue was used for RNA isolation. H&E stained 
sections were used to score the degree of 
morphological degeneration. Briefly, tissue 
sections were scored for the presence of cell 
clusters, the presence of fissures, loss of 
demarcation and loss of haematoxophilia. A score 
of 0 to 4 indicates a histologically normal (non-
degenerate) IVD and a grade of 4.1 - 12 (>4) 
indicates evidence of degeneration. Gene 
expression study samples were classified as non-
degenerate (≤4) and degenerate (>4) based on 
histological examination. Grading was performed 
independently by two researchers and grades 
averaged.   
Plasmids and Reagents - Luciferase reporter 
plasmids were provided by Drs. Ito (26) (TauT-
luc), Collier (28) (WT CXCL1-luc, WT CXCL2-
luc, NF-kB Mut CXCL1-luc, NF-κB Mut CXCL2-
luc), Burg (48) (Ton-TAD, pFR-luc), and 
Taubman (63) (NF-kB-luc). psPAX2 (#12260), 
pMD2G (#12259), and FLAG-p65 (#20012) (64) 
were from Addgene. As transfection control, pRL-
TK (Promega) was used. Lentiviral ShTonEBP 
(TRCN0000020019) and control ShRNA pLKO.1 
were from Sigma.  
Lentiviral Studies - HEK-293T cells in 10-cm 
plates (1.3x106 cells/plate) were transfected with 
9µg of either lentiviral ShCTR (pLKO.1) or 
ShTonEBP plasmids, 6µg psPAX2, 3µg pMD2.G. 
After 16h, media was removed and replaced with 
DMEM with 5% FBS. Lentiviral particles were 
harvested at 48 and 60 h post-transfection and 
concentrated using PEG solution. NP cells were 
transduced with media containing viral particles 
and 8µg/ml polybrene. Cells and conditioned 
medium were collected 5 days post-transduction. 
RNA-Sequencing - Illumina TruSeq Stranded Total 
RNA Sample Prep with Ribo-Zero was used to 
prepare the library. Libraries were chemically 
denatured and applied to an Illumina HiSeq v4 
single read flow cell using an Illumina cBot. 
Hybridized molecules were clonally amplified and 
annealed to sequencing primers with reagents from 
an Illumina HiSeq SR Cluster Kit v4-cBot. After 
transfer of the flowcell to an Illumina HiSeq 2500, 
a 50-cycle single-read sequence run was 
performed (HiSeq SBS Kit v4). For data analysis, 
Rn5 Ensembl annotations (Build 75) were 
downloaded and converted to genePred format. 
Reads were aligned to the transcriptome reference 
index using Novoalign (v2.08.01), allowing up to 
50 alignments for each read. Read counts were 
generated using USeq’s 
DefinedRegionDifferentialSeq application and 
used in DESeq2 to measure the differential 
expression between each condition. Due to 
inherent variability between sets arising from 
independent primary cell isolations, sample 
preparation batch was accounted for during data 
normalization. Data has been deposited to the 
GEO Database (Accession No. GSE97496). For 
Ingenuity Pathway Analysis (IPA), differentially 
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expressed gene lists were used as input to identify 
enriched related pathways, diseases, and networks. 
Real-Time qRT-PCR - For in vitro assays: Total 
DNA-free RNA was extracted from NP cells using 
RNeasy mini columns (Qiagen), and cDNA made 
using EcoDry premix (Clontech). For human 
tissue samples: Extracted RNA was subjected to 
treatment with DNase (Qiagen, Crawley, UK) and 
purified using Qiagen MinElute Cleanup kit prior 
to cDNA synthesis using MMLV Reverse 
Transcriptase (Bioline, London, UK) and random 
hexamers (Invitrogen). Real-time PCR analysis 
was performed using pre-designed, FAM-labeled 
Taqman Gene Expression Assays (Applied 
Biosystems) to determine gene expression of 
TonEBP in 42 IVD patient samples; 2 post-
mortem and 40 surgical. 10 histologically non-
degenerated samples (mean histological grade, 2.7 
(range 1-4); mean age, 36 (range 20-45)) and 32 
histologically degenerated samples (mean 
histological grade, 8.2 (range 4.8-12); mean age, 
40.9 (range 25-66)) were used for this component 
of the study.  
Western Blotting - Cells were placed on ice 
following treatment and washed with ice-cold 
PBS. Buffers included 1X-protease inhibitor 
cocktail (Roche), NaF (4mM) and Na3VO4 
(20mM), NaCl (150mM), β-glycerophosphate 
(50mM), and DTT (0.2mM). Nuclear proteins 
were isolated using the CellLytic NuCLEAR 
extraction kit (Sigma-Aldrich). Proteins were 
resolved on 8% SDS-polyacrylamide gels and 
transferred by electroblotting to PVDF membranes 
(Bio-Rad, CA). Membranes were blocked with 5% 
non-fat dry milk in TBST and incubated overnight 
at 4°C in blocking buffer with Rabbit anti-
TonEBP (1:1000, Abcam, catalog # ab3446, Lot 
GR303959-2), Rabbit anti-Lamin A/C (1:1000, 
Cell Signaling, catalog # 2032), or Mouse anti-β-
tubulin antibody (1:2000, DSHB, catalog # E-7). 
Specificity of the TonEBP antibody has been 
demonstrated previously (6). Immunolabeling was 
detected with ECL reagent. Chemiluminescence 
was detected using Digital Imaging System 
ImageQuant LAS-400 (GE Healthcare). 
Densitometric analysis was performed 
(ImageQuant) by first normalizing protein-of-
interest levels to the housekeeping protein (β-
tubulin) and then normalizing to the experimental 
control group. 
Immunohistochemical Analysis - 
Immunohistochemistry was used to confirm and 
localize expression of TonEBP in 30 IVDs; 2 PM 
and 28 surgical samples (Supplemental Table 4). 
10 histologically non-degenerate samples (mean 
histological grade, 3.4 (range 2-4); mean age, 35.9 
(range 21-46)) and 20 histologically degenerate 
samples (mean histological grade, 7.7 (range 5-
11); mean age, 44.1 (range 18-74)) were used. 4 
µm tissue sections were dewaxed, rehydrated and 
endogenous peroxidases blocked. Following heat 
antigen retrieval, sections were blocked in goat 
serum and incubated overnight at 4°C with rabbit 
polyclonal antibody against human TonEBP 
(1:100; Abcam, catalog # ab3446, Lot GR223014-
6). Rabbit polyclonal IgG (Abcam, catalog # 
ab27478, Lot GR166285-4) was used as a negative 
control. After washing, sections were incubated 
with biotinylated goat anti-rabbit antibody (1:500; 
Abcam, catalog # ab97049, Lot GR137025-3). 
Binding was detected using VECTASTAIN Elite 
ABC HRP Reagent (Vector Laboratories, 
Peterborough, UK) and 3, 3'-diaminobenzidine 
tetrahydrochloride solution (Sigma-Aldrich). 
Sections were counterstained with Mayers 
Haematoxylin (Leica Microsystems, Milton 
Keynes, UK), dehydrated, cleared and mounted in 
Pertex (Leica Microsystems). Images were 
captured using an Olympus BX60 microscope, 
QImaging Micropublisher 5.0 RTV camera and 
QCapture Pro v8.0 software (MediaCybernetics, 
Marlow, UK) with Olympic UPlan F1 40X or 
100X objective. A total of 200 NP cells were 
counted in each section and the number of 
immunopositive cells expressed as a percentage of 
total count. 
Immunofluorescence - NP cells were plated on 
glass coverslips. After incubation with various 
stimuli, cells were fixed and permeabilized with 
ice-cold methanol for 15 minutes, blocked with 
PBS containing 5% normal goat serum and 0.3% 
Triton-X for 1 h at room temperature, and 
incubated with anti-TonEBP (1:150, Abcam) at 
4°C overnight. Cells were washed and incubated 
with Alexa-fluor-594-conjugated anti-rabbit 
antibody (1:800, Jackson Labs). After washing, 
cells were mounted with DAPI-containing 
mountant (Invitrogen) and visualized using a 
fluorescence microscope (Zeiss Axio Imager A2 
and imaged with Axiocam mRm camera and Plan 
Apochromat 63× objective). 
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ELISA and Dot Blot - Conditioned medium was 
filtered (0.45µm) and supplemented with 1X 
protease inhibitor cocktail (Roche). ELISA was 
performed using Mini ELISA Kits for CCL2 and 
IL-6 (Peprotech). CINC1/CXCL1, 
CINC3/CXCL2, and CINC2/CXCL3 were 
detected using the RayBio Rat Cytokine Antibody 
Array 2 (Ray Biotech Inc., Norcross, GA) 
following manufacturer’s instructions. Membranes 
were blocked, incubated with conditioned 
medium, incubated with biotin-conjugated primary 
antibody mixture and then HRP-conjugated 
secondary antibody. Chemiluminescence was 
detected using Digital Imaging System 
ImageQuant LAS-400 (GE Healthcare). 
Bioinformatic Analysis of Promoters and TonE 
Prediction - Rat CXCL1 and CXCL2 promoter 
sequences were downloaded from the UCSC 
Genome Table Browser. MatInspector 
(Genomatix) was used to identify predicted 
TonEBP binding sites (TonE’s), with score cutoff 
of 0.8.  Ensembl browser was used for Multiz 
alignments of TonE’s predicted in the rat promoter 
against human genome.  
Transfections and Dual Luciferase Assay - Cells 
were transferred to 48-well plates (2 × 104 
cells/well) one day prior to transfection. To 
measure effects of stimuli on TauT-luc activity, 
cells were transfected with 250 ng of TauT 
promoter reporter and 250 ng pRL-TK plasmid 
and cultured in control, hypertonic, TNF-α-, IL-
1β-, or LPS-treatment conditions. For gain- and 
loss-of-function studies, FLAG-TonEBP, FLAG-
DN-TonEBP, or backbone plasmid (150ng) was 
co-transfected with CXCL1, CXCL2, or NF-κB 
reporter and pRLTK. For experiments with p65 
overexpression, 15 ng FLAG-p65 or backbone 
was added along with reporter plasmid, FLAG-
TonEBP or FLAG-DN-TonEBP, and pRLTK. In 
all experiments, plasmids were premixed with the 
transfection reagent, LipofectAMINE 2000 
(Invitrogen). 48 h after transfection, cells were 
harvested and firefly and Renilla luciferase 
activities were measured using the Dual-
Luciferase™ reporter assay (Promega) and a 
luminometer (Tecan Infinite M200). 
Site-directed Mutagenesis - Site-directed 
mutagenesis of the rat CXCL1 promoter was 
performed according to the manufacturer’s 
protocol, using the Q5 Site-Directed Mutagenesis 
Kit (New England Biolabs). Primers used for 
CXCL1 promoter mutants are (mutated TonE 
underlined): forward, 5’-
CCGGTTGTGGTTCCACACCCTGTG-3’; 
reverse, 5’-AAAGGACATCGCTCCTCC-3’. 
Mutations were verified by sequencing (Applied 
Biosystems 3730 DNA Sequencer). 
Statistics - For quantitative measurements, results 
are presented as the mean ± S.E. Differences 
between groups were assessed by ANOVA and 
Student’s t-test using GraphPad Prism Software. 
P-values < 0.05 were considered statistically 
significant. Human expression data was non-
parametric, thus Kruskal-Wallis test with post-hoc 
analysis by Conover-Inman test was used to 
determine significance between 2ΔCT values and 
percentage immunopositivity between groups. 
Spearman's rank correlation was used to determine 
correlations between gene and expression for 
different targets.
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Figure Legends 
Figure 1. TNF-α  promotes nuclear localization of TonEBP without affecting transcript levels. A) 
TonEBP mRNA levels were unaffected by treatment with TNF-α, IL-1β, or LPS for 4 to 24 h; as 
expected, treatment with NaCl (110 mM) resulted in induction. B, C) Levels of total cellular TonEBP did 
not change with TNF-α treatment for 4 to 24 h. D, E) Nuclear and cytoplasmic fraction experiment 
clearly shows increased nuclear accumulation of TonEBP following TNF-α treatment for 24 h. No 
discernable depletion of TonEBP in cytoplasmic fraction was seen. Lamin  and β-tubulin loading controls 
showed relatively high purity of fractions.  F-I) Treatment with IL-1β (F, G) and LPS (H, I) for 4 to 24 h 
did not affect amount of nuclear TonEBP protein. J) Immunofluorescent detection of TonEBP in NP cells 
following 24 h treatment with NaCl or TNF-α. Insert shows high magnification image of cells. Scale bar: 
100 µm. Quantitative measurements represent mean ± SEM of ≥ 3 biological replicates. *P ≤ 0.05, **P ≤ 
0.01, ***P ≤ 0.001, ****P ≤ 0.0001.  
 
Figure 2. TonEBP activation under inflammatory conditions fails to induce transcription of its 
canonical osmo-regulatory target genes. A) Cartoon depicting binary TonTAD-GAL4 system used to 
measure TonEBP-TAD activity. B) Activity of TonEBP-TAD was unaffected by treatment with TNF-α, 
IL-1β, or LPS alone, but induced, by NaCl. Co-treatment with TNF-α and NaCl dampened the TAD 
activation by NaCl alone. C) Diagram showing taurine transporter (TauT) luciferase reporter, which 
contains an active, highly conserved, TonEBP binding site, TonE. D) While treatment with NaCl induced 
activity of the TauT promoter, treatment with TNF-α, IL-1β, or LPS had no effect. E-G) TauT (E), SMIT 
(F), and AR (G) mRNA levels did not significantly increase with TNF-α, IL-1β, or LPS treatment for 4 to 
24 h, while 8 h NaCl treatment results in induction. H) Co-treatment of TNF-α along with NaCl did not 
affect NaCl-mediated induction of TauT, SMIT, or AR. Quantitative measurements represent mean ± SEM 
of ≥ 3 biological replicates and, for transfection experiments, 3 technical replicates per biological 
replicate. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.  
 
Figure 3. RNA sequencing reveals TonEBP as an important regulator of NP cell response to TNF-
α . NP cells were transduced with either ShControl or ShTonEBP and cultured with or without TNF-α for 
24 h and RNA-sequencing was performed. A) Heatmap depicting genes differentially expressed between 
shControl and shTonEBP under either basal or TNF-α stimulated (24 h TNF-α) conditions. B) Venn 
diagram showing overlap between TonEBP-dependent genes in untreated vs. TNF-α-treated cells. C) 
Heatmap depicting genes differentially expressed between control and TNF-α treatment groups. D) 
Volcano plot depicting expression of transcripts that are differentially expressed between control and 
TNF-α treatment groups and controlled by TonEBP under TNF-α treatment. E) Venn diagrams showing 
overlap between genes positively or negatively regulated by TNF-α and also regulated by TonEBP. F) 
Log2(-Fold Change) values for inflammation-related transcripts that were differentially expressed 
between control and TonEBP-knockdown under TNF-α treatment; genes shown were statistically 
significant between the indicated experimental groups, as defined by adjusted p-value < 0.05. 
Quantitative measurements represent mean ± SEM of ≥ 3 biological replicates. *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001, ****P ≤ 0.0001.  
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Figure 4. TonEBP regulates TNF-α-dependent expression of select genes linked to matrix 
catabolism. A) qRT-PCR confirmation of TonEBP knockdown. TonEBP and TauT mRNA levels were 
unaffected by TNF-α treatment in ShControl-transduced cells but decreased in cells transduced with 
ShTonEBP. B) TonEBP regulated transcript levels of matrix catabolic enzymes ADAMTS4, ADAMTS5, 
and MMP3 under TNF-α treatment. C) TNF-α treatment significantly decreases transcript levels of 
ACAN and COL2A1 in ShControl-transduced cells. Levels were unaffected by knockdown of TonEBP. 
Quantitative measurements represent mean ± SEM of ≥ 3 biological replicates. *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001, ****P ≤ 0.0001.  
 
Figure 5. TonEBP controls TNF-α-mediated induction of key cytokines, chemokines, and 
inflammatory molecules in NP cells. A) TNF-α treatment induced expression of TNF, NOS2, PHD3, 
and TLR2 mRNAs, which was significantly inhibited by TonEBP knockdown. B, C) Expression level of 
CCL2 and IL-6 mRNA (B) and CCL2 protein (C) were induced by TNF-α treatment; this induction was 
blocked by TonEBP knockdown. D) IL-6 protein levels were decreased by TonEBP knockdown under 
TNF-α treatment condition. E, F) CXCL1/CINC1, CXCL2/CINC3, and CXCL3/CINC2 mRNA (E) and 
protein (F) levels were induced by TNF-α in cell transduced with ShControl and significantly decreased 
by TonEBP knockdown. Quantitative measurements represent mean ± SEM of ≥ 3 biological replicates. 
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.  
 
Figure 6. TonEBP controls the activity of the CXCL1 promoter via a highly conserved NF-κB 
binding site. A) Diagram showing predicted TonEBP and NF-κB binding sites in the rat CXCL1 
proximal promoter spanning -1.5 kb upstream of the transcription start site. Predicted TonE is depicted by 
grey circle and NF-κB binding sites by open squares. NF-κB-mutant reporter contains mutation in 
binding site #2 (starred), which has high species conservation and activity in other cell types. B) Under 
basal conditions, TonEBP increased activities of WT and TonE-mutant promoters while NF-κB-mutant 
was unaffected. C) WT, TonE-, and NF-κB-mutant reporters were all induced by TNF-α treatment. 
During TNF-α treatment, addition of TonEBP further induced activity of WT and TonE-mutant reporters 
only. D) WT and TonE-mutant reporters, but not NF-κB-mutant, were induced by IL-1β treatment. 
During IL-1β stimulation, addition of TonEBP did not affect inducibilty of any of the reporters, while 
DN-TonEBP blocked induction of WT and TonE-mutant reporters. E) None of the reporters responded to 
LPS treatment alone. Addition of TonEBP during LPS treatment induced activity in WT and TonE-
mutant reporters only. F) Addition of small amount (15 ng) of p65 plasmid resulted in a trend of increased 
activity in all reporters, which was further enhanced by addition of TonEBP. G) Expression of TonEBP 
further increased TNF-α-dependent induction of NF-κB reporter activity. H) Treatment with TNF-α, but 
not NaCl, induced mRNA expression of CXCL1. TNF-α-mediated induction was unaffected by co-
treatment with NaCl. Quantitative measurements represent mean ± SEM of ≥ 3 biological replicates and, 
for transfection experiments, 3 technical replicates per biological replicate. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 
0.001, ****P ≤ 0.0001.  
 
Figure 7. TonEBP controls the CXCL2 promoter only under certain stimulatory conditions. 
A) Diagram showing predicted TonEBP and NF-κB binding sites in the rat CXCL2 proximal promoter 
spanning -1.5 kb upstream of the transcription start site. TonE’s are depicted by grey circles and NF-κB 
binding sites by open squares. NF-κB-mutant reporter contains mutation in binding site #2 (starred), 
which has high species conservation and activity in other cell types. B) WT and NF-κB-mutant (to a 
smaller extent) reporters were induced by TNF-α, while further addition of TonEBP or DN-TonEBP had 
no effect. C) WT reporter was induced by IL-1β, and further addition TonEBP or DN-TonEBP had no 
effect on reporter activity. D) LPS induced WT reporter activity, with further enhancement by addition of 
TonEBP. E) Addition of small amount of p65 plasmid induced activity of both reporters. Addition of 
TonEBP along with p65 resulted in further induction of the NF-κB-mutant; there was a small trend of 
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increase for the WT promoter. F) Treatment with TNF-α, but not NaCl, increased CXCL2 mRNA 
expression. TNF-α-dependent induction was unaffected by co-treatment with NaCl. Quantitative 
measurements represent mean ± SEM of ≥ 3 biological replicates and, for transfection experiments, 3 
technical replicates per biological replicate. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.  
 
Figure 8. TonEBP expression is correlated with levels of osmo-protective genes in human NP 
samples. A, Immunohistochemical staining of TonEBP in non-degenerated (grades ≤4) and degenerated 
(grades >4) human NP samples. Isotype IgG was used as negative control for staining. B) Percentage of 
cells immunopositive for TonEBP was not significantly different between non-degenerated and 
degenerated tissue samples. C-E) Correlation between mRNA levels of TonEBP and osmo-regulatory 
target genes TauT (p=0.0044) (C), SMIT (p=0.03) (D), and AR (p=0.0554) (E) was seen in all tissue 
samples analyzed. F) Schematic of proposed regulation of TonEBP by TNF-α and downstream 
transcriptional responses. Activation by either TNF-α or NaCl induces nuclear abundance of TonEBP, but 
only NaCl induces TonEBP transcript levels. Upon stimulation with TNF-α, TonEBP participates in 
crosstalk with NF-κB family members to promote transcription of pro-inflammatory genes. In A, Scale 
bar for X40 images (left) is 100µm and scale bar for X100 images (right) is 50 µm.  
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